Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.
Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.
Despite FDA warnings that patients who stopped treatment of Amgen's Prolia had a high risk of fractures, a consumer watchdog is calling for more.
Pharma’s reputation is holding steady with patient groups with an annual study finding 41% giving pharma good marks, similar to 43% the year before.
WuXi Biologics says its plant in Wuxi, China, has gotten the go-ahead from the FDA to make HIV drug Trogarzo for TaiMed Biologics.
As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.
Allergan’s digital booking platform for aesthetic treatments helps consumers find Allergan-branded medical aesthetics but also regular spa services.
United Therapeutics faces allegations of illegally blocking Remodulin generics by teaming with a devicemaker.
As sales of blockbuster lung drug Spiriva flagged in 2018, Boehringer Ingelheim needed a boost from other divisions. Turns out diabetes was the key.
Last July, Roche put a halt on U.S. price hikes. But that didn't stop five of its products from topping analysts' estimates by double digits in Q1.